Germany · Delayed Price · Currency is EUR SELLAS Life Sciences Group Company Description
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009.
SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 15 |
| CEO | Angelos Stergiou |
Contact Details
Address: 7 Times Square New York, Delaware 10036 United States | |
| Phone | 646 200 5278 |
| Website | sellaslifesciences.com |
Stock Details
| Ticker Symbol | RXK3 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Angelos Stergiou | Chief Executive Officer |
| John Burns | Chief Financial Officer |